Healthcare, Regulatory and Reimbursement Landscape - TurkeyReport Details:Published:November 2012No. of Pages: 169Price: S...
technology.Scope- Overview of Turkey’s pharmaceutical and medical device markets, including size, segmentationand key driv...
3 Overview of Pharmaceutical and Medical Devices Markets 123.1 Pharmaceutical Market 123.1.1 Market Overview 123.1.2 Suppl...
5.3.3 Inflation 1075.3.4 Currency Exchange Rate 1105.3.5 Foreign Direct Investment 1115.3.6 Foreign Exchange Reserves 1125...
7.5 Disclaimer 1691.1 List of TablesTable 1: Pharmaceutical Market, Turkey, Revenue ($bn), 2005-2010 13Table 2: Pharmaceut...
Table 40: GDP Per Capita ($’000), Turkey, 2006-2011 104Table 41: GDP Per Capita, Forecast ($’000), Turkey, 2012-2020 105Ta...
Table 82: CT Scan Units in Hospitals (Per 100,000 Population), Turkey, 2005-2010 141Table 83: Beds (Per 1,000 Population),...
Figure 21: Diagnostic Imaging Devices Market, Turkey, Revenue ($m), 2006-2011 58Figure 22: Sales Trends for Major Players*...
Figure 64: Life Expectancy at Birth Forecast (Years), Turkey, 2011-2020 133Figure 65: Levels of Education, Turkey, Gross E...
Upcoming SlideShare
Loading in...5
×

Healthcare, Regulatory and Reimbursement Landscape - Turkey

165

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
165
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
5
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "Healthcare, Regulatory and Reimbursement Landscape - Turkey"

  1. 1. Healthcare, Regulatory and Reimbursement Landscape - TurkeyReport Details:Published:November 2012No. of Pages: 169Price: Single User License – US$1995Healthcare, Regulatory and Reimbursement Landscape - TurkeySummaryGlobalData, the industry analysis specialist, has released its latest report, “Healthcare, Regulatoryand Reimbursement Landscape - Turkey”. It is an essential source of information and analysis onTurkey’s healthcare, regulatory and reimbursement landscape. It identifies the key trends in thehealthcare market and provides insights into the demographic, regulatory and reimbursementlandscape and healthcare infrastructure. Most importantly, the report provides valuable insightsinto the trends and segmentation of the pharmaceutical and medical device markets. It is builtusing data and information sourced from proprietary databases, secondary research and in-houseanalysis by GlobalData’s team of industry experts.The population of Turkey has increased significantly over the years. In 2011, Turkey had apopulation of approximately 74 million. The overall population increased between 2006 and 2011from 69.4 to 74.0 million, mainly due to the increasing life expectancy. In 2011, Turkey was the17th most populated nation in the world. As is the case in most developed countries, the elderlypopulation is increasing and in 2012 comprises more than 10% of the population. The working agegroup contributes more than 50% of the total population and is expected to reach 56.3% of thetotal population by 2020, resulting in an increase in the available labor pool in the country.In 2010, the pharmaceutical market of Turkey was approximately $9.8 billion and Turkey was thesixth largest pharmaceutical market in Europe. The pharmaceutical market is to grow at aCompound Annual Growth Rate (CAGR) of 6.1% from 2005 to 2020, and is estimated to reach$21.6 billion in 2020.The market for medical devices in Turkey is large due to the increasing elderly population andsubsequent increase in the demand for healthcare products and services. The medical devicemarket in Turkey was valued at approximately $1.8 billion in 2006. It grew at a CAGR of 4.8% from2006 to 2011 and reached $2.2 billion in 2011. The market is predicted to reach to $3.3 billion by2020. Turkey predominantly depends on imports for the medical devices. Turkey has a largenumber of domestic producers also but these are involved with products which do not require high
  2. 2. technology.Scope- Overview of Turkey’s pharmaceutical and medical device markets, including size, segmentationand key drivers and barriers- Profiles and SWOT analyses of the major players in the pharmaceutical and medical devicemarkets. Key players in the pharmaceutical market are Abdi Ibrahim, Novartis, Sanofi, Bilim andPfizer. Key players in the medical devices market are Siemens Healthcare, Roche, Essilor,Fresenius and Baxter.- Insightful review of the reimbursement and regulatory landscape, comprising details of thehealthcare reimbursement process, regulatory agencies and approval processes for new drugsand medical devices- Detailed analysis of Turkey’s political and economic environment, including economic indicators,demographics, healthcare infrastructure and healthcare expenditure- An overview of the opportunities for and challenges to growth in the healthcare marketReasons to buyThis report comprehensively covers Turkey’s pharmaceutical and medical device markets and willenhance your decision-making capability by allowing you to -- Develop business strategies by understanding the trends shaping and driving Turkey’shealthcare market- Drive revenues by understanding key trends, reimbursement and regulatory policies,pharmaceutical and medical device market segments and companies likely to impact thehealthcare market in the future- Formulate effective sales and marketing strategies by understanding the competitive landscapeand analyzing the performance of various competitors- Organize your sales and marketing efforts by identifying the market categories and segmentsthat present the most opportunities for consolidation, investment and strategic partnerships- Identify, understand and capitalize on the opportunities and challenges in Turkey’s healthcaremarketGet your copy of this report @http://www.reportsnreports.com/reports/209355-healthcare-regulatory-and-reimbursement-landscape-turkey.htmlMajor points covered in Table of Contents of this report include1 Table of Contents1 Table of Contents 51.1 List of Tables 71.2 List of Figures 92 Introduction 112.1 Report Guidance 11
  3. 3. 3 Overview of Pharmaceutical and Medical Devices Markets 123.1 Pharmaceutical Market 123.1.1 Market Overview 123.1.2 Supply Channels 143.1.3 Market Segments 153.1.4 Major Therapeutic Areas 203.1.5 Major Players 223.2 Medical Device Market 473.2.1 Market Overview 473.2.2 Overview of Top Five Segments 493.2.3 Major Players 603.3 Market Drivers and Barriers 833.3.1 Market Drivers 833.3.2 Market Barriers 834 Market Access 854.1 Reimbursement and Payer Landscape 854.1.1 Overview of Healthcare System 854.1.2 Reimbursement Process 884.1.3 Overview of Insurance Providers 894.1.4 Patient Share in Healthcare Spending 904.1.5 Pricing Trends in Healthcare Industry 914.1.6 Pricing Policies 914.2 Regulatory Landscape 924.2.1 Overview of Regulatory Agencies 924.2.2 Drug Approval Process 924.2.3 New Device Approval Process 944.2.4 Licensing Process for Manufacturing 954.2.5 Licensing Process for Pharmaceutical Imports 964.2.6 Intellectual Property Rights Landscape 964.2.7 Clinical Trial Regulations 964.2.8 Pharmaceutical Advertising Regulations 974.2.9 Pharmacy Regulations 984.2.10 Labeling and Packing Regulations 995 Country Analysis 1005.1 Political Environment 1005.1.1 Political Structure 1005.1.2 Analysis of the Current Political Environment 1015.1.3 Healthcare Policy Initiatives 1025.2 Economic Landscape 1035.3 Economic Indicators 1045.3.1 Gross Domestic Product 1045.3.2 Gross National Income 106
  4. 4. 5.3.3 Inflation 1075.3.4 Currency Exchange Rate 1105.3.5 Foreign Direct Investment 1115.3.6 Foreign Exchange Reserves 1125.3.7 Trade Balance 1135.3.8 Government Structural Balance 1155.3.9 Government Net Debt 1165.3.10 Major Industries 1175.4 Demographics 1185.4.1 Population 1185.4.2 Education and Literacy 1335.4.3 Employment 1365.4.4 Disease Burden 1385.5 Healthcare Infrastructure 1395.5.1 Healthcare Facilities 1395.5.2 Healthcare Parameters 1425.5.3 Environmental Health 1445.5.4 Healthcare Personnel 1485.6 Healthcare Expenditure 1515.6.1 Overview 1515.6.2 Health and Drug Expenditure 1535.6.3 Health Expenditure Per Capita 1555.6.4 Public and Private Sector Share 1565.6.5 Spending on Pharmaceutical R&D 1575.7 Trade Associations 1585.7.1 Turkish Pharmacists’ Association 1585.7.2 Pharmaceutical Manufacturer’s Association of Turkey 1585.7.3 Turkish Confederation of Employer Associations 1585.8 Trade Fairs 1596 Opportunities and Challenges 1606.1 Opportunities 1606.2 Challenges 1617 Appendix 1627.1 Abbreviations 1627.2 Bibliography 1637.3 Methodology 1677.3.1 Coverage 1677.3.2 Secondary Research 1677.3.3 Forecasting 1687.3.4 Primary Research 1687.3.5 Expert Panel Validation 1687.4 Contact Us 168
  5. 5. 7.5 Disclaimer 1691.1 List of TablesTable 1: Pharmaceutical Market, Turkey, Revenue ($bn), 2005-2010 13Table 2: Pharmaceutical Market, Turkey, Revenue Forecast ($bn), 2011-2020 14Table 3: Supply Chain Margin, Turkey, Wholesaler and Pharmacist Profit (%), 2007 14Table 4: Generic Market, Turkey, Revenue ($bn), 2006-2011 15Table 5: Generic Market, Turkey, Revenue Forecast ($bn), 2012-2020 16Table 6: Drugs Going Off-patent, Global, Revenue ($bn), 2011-2015 17Table 7: OTC Pharmaceutical Market, Turkey, Revenue ($m), 2005-2010 18Table 8: OTC Pharmaceutical Market, Turkey, Revenue Forecast ($m), 2011-2020 18Table 9: OTC Pharmaceutical Market, Turkey, Segment Share (%), 2005 19Table 10: Pharmaceutical Market, Turkey, Major Therapeutic Areas (%), 2007 20Table 11: Major Products, Abdi Ibrahim, 2012 22Table 12: Major Products, Novartis, Global, Revenue ($m), 2011 25Table 13: Planned Filings, Novartis, 2012 to = 2016 26Table 14: Major Products, Sanofi, Global, Revenue ($m), 2011 31Table 15: Late-stage Pipeline, Sanofi, 2012 32Table 16: Major Products, Pfizer, Global, Revenue ($m), 2011 40Table 17: Late-stage Pipeline, Pfizer, 2012 41Table 18: Medical Device Market, Turkey, Revenue ($bn), 2006-2011 47Table 19: Medical Device Market, Turkey, Revenue Forecast ($bn), 2012-2020 48Table 20: Medical Device Market, Turkey, Segments, Revenue ($m), 2011 49Table 21: Ophthalmic Devices Market, Turkey, Revenue ($m), 2006-2011 50Table 22: Sales Trends for Major Players*, Ophthalmic Devices, Turkey, 2010 51Table 23: In Vitro Diagnostics Device Market, Turkey, Revenue ($m), 2006-2011 52Table 24: Sales Trends for Major Players*, In Vitro Devices, Turkey, 2010 53Table 25: Nephrology and Urology Devices Market, Turkey, Revenue ($m), 2006-2011 54Table 26: Sales Trends for Major Players*, Nephrology and Urology Devices, Turkey, 2010 55Table 27: Orthopedic Device Market, Turkey, Revenue ($m), 2006-2011 56Table 28: Sales Trends for Major Players*, Orthopedic Devices, Turkey, 2010 57Table 29: Diagnostic Imaging Devices Market, Turkey, Revenue ($m), 2006-2011 58Table 30: Sales Trends for Major Players*, Diagnostic Imaging Devices, Turkey, 2010 59Table 31: Major Medical Device Companies, Turkey, Revenue ($m), 2010 60Table 32: Major Products, Siemens, Global, Revenue ($m), 2010 61Table 33: Major Products, Roche, Global, Revenue ($m), 2010 64Table 34: Late-stage Pipeline, F. Hoffmann-La Roche Ltd., 2012 65Table 35: Major Products, Fresenius Medical, 2012 72Table 36: Major Products, Baxter International, Global, Revenue ($m), 2010 79Table 37: Healthcare Spending, Turkey, Patient Share (%), 2005-2010 90Table 38: Healthcare Industry, Turkey, Price Change (%), 2006-2011 91Table 39: Reimbursement Agency, Turkey, Pharmaceutical Discount (%), 2011 98
  6. 6. Table 40: GDP Per Capita ($’000), Turkey, 2006-2011 104Table 41: GDP Per Capita, Forecast ($’000), Turkey, 2012-2020 105Table 42: GDP, Turkey, Annual Growth (%), 2006-2011 105Table 43: GDP, Turkey, Annual Growth Forecast (%), 2012-2020 106Table 44: GNI Per Capita ($’000), Turkey, 2006-2011 106Table 45: Average Consumer Price Index, Turkey, Annual Change (%), 2006-2011 107Table 46: Average Consumer Price Index, Turkey, Annual Change Forecast, 2012-2020 108Table 47: Average Consumer Price, Turkey, Annual Change (%), 2006-2011 109Table 48: Average Consumer Price, Turkey, Annual Change Forecast (%), 2012-2020 109Table 49: Currency Exchange Rate (TRY/$), Turkey, 2006-2011 110Table 50: Foreign Direct Investment Inflow ($bn), Turkey, 2006-2011 111Table 51: Foreign Exchange Reserves ($bn), Turkey, 2006-2011 112Table 52: Exports of Goods and Services ($bn), Turkey, 2006-2011 113Table 53: Imports of Goods and Services ($bn), Turkey, 2006-2011 114Table 54: General Government Structural Balance ($bn), Turkey, 2005-2010 115Table 55: General Government Structural Balance, Turkey, Forecast ($bn), 2011-2020 115Table 56: General Government Net Debt ($bn), Turkey, 2005-2010 116Table 57: General Government Net Debt, Turkey, Forecast ($bn), 2011-2020 116Table 58: Major Industries, Turkey, Turnover ($bn), 2008 117Table 59: Population (m), Turkey, 2006-2011 118Table 60: Population, Turkey, Forecast (m), 2012-2020 119Table 61: Urban and Rural Population, Turkey, Share (%), 2005-2010 120Table 62: Urban and Rural Population, Turkey, Forecast Share (%), 2011-2020 121Table 63: Age Groups, Turkey, Population Distribution (%), 2005-2010 122Table 64: Age Groups, Turkey, Population Distribution Forecast (%), 2011-2020 123Table 65: Births (Per 1,000 Population) Turkey, 2005-2010 124Table 66: Mortality Rate (Per 1,000 Population), Turkey, 2005-2010 125Table 67: Major Causes of Mortality (‘000), Turkey, 2008 126Table 68: Children Table 69: Immunization Rate (%), Turkey, 2005-2010 128Table 70: Major Causes of Male Mortality, Turkey (‘000), 2008 129Table 71: Major Causes of Female Mortality (‘000), Turkey, 2008 130Table 72: Gender Ratio (M/F), Turkey, 2005-2010 131Table 73: Life Expectancy at Birth (Years), Turkey, 2005-2010 132Table 74: Life Expectancy at Birth Forecast (Years), Turkey, 2011-2020 133Table 75: Levels of Education, Turkey, Gross Enrolment (%), 2009 134Table 76: Students Enrolled (m), Turkey, 2005-2010 135Table 77: Unemployment Rate (%), Turkey, 2006-2011 136Table 78: Employment, Turkey, Pharmaceutical Sector, Number of Employees (‘000), 1987-2007137Table 79: Major Diseases, Turkey, DALYs (Per 100,000 Population), 2004 138Table 80: Public and Private Hospitals, Turkey, 2005-2010 139Table 81: MRI Units in Hospitals (Per 100,000 Population), Turkey, 2005-2010 140
  7. 7. Table 82: CT Scan Units in Hospitals (Per 100,000 Population), Turkey, 2005-2010 141Table 83: Beds (Per 1,000 Population), Turkey, 2005-2010 142Table 84: Physicians (Per 1,000 Population), Turkey, 2005-2010 143Table 85: Physicians (Per 1,000 Population), Forecast, Turkey, 2011-2020 144Table 86: CO2 Emissions (Metric Tons), Turkey, 2005-2010 145Table 87: Deaths Attributable to the Environment (Per 100,000 Population), Turkey, 2004 146Table 88: PM10 (µg/m3), Turkey, 2005-2010 147Table 89: Nurses (Per 1,000 Population), Turkey, 2005-2010 148Table 90: Pharmacists (Per 100,000 Population), Turkey, 2005-2010 149Table 91: Distribution of Pharmacists by Region, Turkey, 2003 149Table 92: Dentists (Per 100,000 Population), Turkey, 2005-2010 150Table 93: Healthcare Expenditure (% of GDP), Turkey, 2005-2010 151Table 94: Healthcare Expenditure (% of GDP), Turkey, Forecast, 2011-2020 152Table 95: Total Health and Drug Expenditure ($m), Turkey, 2000-2007 153Table 96: Total Health and Drug Expenditure (%), Turkey, 2000-2007 154Table 97: Healthcare Expenditure Per Capita ($), Turkey, 2001-2007 155Table 98: Healthcare Expenditure, Turkey, Public-Private Share (%) 2005-2010 156Table 99: Health R&D Expenditure ($m), Turkey, 2005-2010 157Table 100: Major Healthcare Trade Fairs, Turkey, 2012 1591.2 List of FiguresFigure 1: Pharmaceutical Market, Turkey, Imported and Local Drugs (%), 2007 13Figure 2: Pharmaceutical Market, Turkey, Revenue ($bn), 2005-2010 13Figure 3: Pharmaceutical Market, Turkey, Revenue Forecast ($bn), 2011-2020 14Figure 4: Generic Market, Turkey, Revenue ($bn), 2006-2011 15Figure 5: Generic Market, Turkey, Revenue Forecast ($bn), 2012-2020 16Figure 6: OTC Pharmaceutical Market, Turkey, Revenue ($m), 2005-2010 18Figure 7: OTC Pharmaceutical Market, Turkey, Revenue Forecast ($m), 2011-2020 18Figure 8: OTC Pharmaceutical Market, Turkey, Segment Share (%), 2005 19Figure 9: Pharmaceutical Market, Turkey, Major Therapeutic Areas (%), 2007 20Figure 10: Medical Device Market, Turkey, Revenue ($bn), 2006-2011 47Figure 11: Medical Device Market, Turkey, Revenue Forecast ($bn), 2012-2020 48Figure 12: Medical Device Market, Turkey, Segments, Revenue ($m), 2011 49Figure 13: Ophthalmic Devices Market, Turkey, Revenue ($m), 2006-2011 50Figure 14: Sales Trends for Major Players*, Ophthalmic Devices, Turkey, 2006-2010 51Figure 15: In Vitro Diagnostics Device Market, Turkey, Revenue ($m), 2006-2011 52Figure 16: Sales Trends for Major Players*, In Vitro Devices, Turkey, 2006-2010 53Figure 17: Nephrology and Urology Devices Market, Turkey, Revenue ($m), 2006-2011 54Figure 18: Sales Trends for Major Players*, Nephrology and Urology Devices, Turkey, 2006-201055Figure 19: Orthopedic Device Market, Turkey, Revenue ($m), 2006-2011 56Figure 20: Sales Trends for Major Players*, Orthopedic Devices, Turkey, 2006-2010 57
  8. 8. Figure 21: Diagnostic Imaging Devices Market, Turkey, Revenue ($m), 2006-2011 58Figure 22: Sales Trends for Major Players*, Diagnostic Imaging, Turkey, 2006-2010 59Figure 23: Major Medical Device Companies, Turkey, Revenue ($m), 2010 60Figure 24: Drivers and Barriers, Healthcare Market, Turkey, 2011 84Figure 25: Organization Structure of SGK, Turkey, 2012 86Figure 26: Reimbursement Process, Turkey, 2011 88Figure 27: Healthcare Spending, Turkey, Patient Share (%), 2005-2010 90Figure 28: Healthcare Industry, Turkey, Price Change (%), 2006-2011 91Figure 29: Major Health Reforms, Turkey, 2003-2008 102Figure 30: GDP Per Capita ($’000), Turkey, 2006-2011 104Figure 31: GDP Per Capita, Forecast ($’000), Turkey, 2012-2020 105Figure 32: GDP, Turkey, Annual Growth (%), 2006-2011 105Figure 33: GDP, Turkey, Annual Growth Forecast (%), 2012-2020 106Figure 34: GNI Per Capita ($’000), Turkey, 2006-2011 106Figure 35: Average Consumer Price Index, Turkey, Annual Change (%), 2006-2011 107Figure 36: Average Consumer Price Index, Turkey, Annual Change Forecast (%), 2012-2020 108Figure 37: Average Consumer Price, Turkey, Annual Change (%), 2006-2011 109Figure 38: Average Consumer Price, Turkey, Annual Change Forecast (%), 2012-2020 109Figure 39: Currency Exchange Rate (TRY/$), Turkey, 2006-2011 110Figure 40: Foreign Direct Investment Inflow ($bn), Turkey, 2006-2011 111Figure 41: Foreign Exchange Reserves ($bn), Turkey, 2006-2011 112Figure 42: Exports of Goods and Services ($bn), Turkey, 2006-2011 113Figure 43: Imports of Goods and Services ($bn), Turkey, 2006-2011 114Figure 44: General Government Structural Balance ($bn), Turkey, 2005-2010 115Figure 45: General Government Structural Balance, Turkey, Forecast ($bn), 2011-2020 115Figure 46: General Government Net Debt ($bn), Turkey, 2005-2010 116Figure 47: General Government Net Debt, Turkey, Forecast ($bn), 2011-2020 116Figure 48: Major Industries, Turkey, Turnover ($bn), 2008 117Figure 49: Population (m), Turkey, 2006-2011 118Figure 50: Population (m), Turkey, Forecast, 2012-2020 119Figure 51: Urban and Rural Population, Turkey, Share (%), 2005-2010 120Figure 52: Urban and Rural Population, Turkey, Forecast Share (%), 2011-2020 121Figure 53: Age Groups, Turkey, Population Distribution (%), 2005-2010 122Figure 54: Age Groups, Turkey, Population Distribution Forecast (%), 2011-2020 123Figure 55: Births (Per 1,000 Population), Turkey, 2005-2010 124Figure 56: Mortality Rate (Per 1,000 Population), Turkey, 2005-2010 125Figure 57: Major Causes of Mortality (‘000), Turkey, 2008 126Figure 58: Children Figure 59: Immunization Rate, Turkey (%), 2005-2010 128Figure 60: Major Causes of Male Mortality, Turkey (‘000), 2008 129Figure 61: Major Causes of Female Mortality (‘000), Turkey, 2008 130Figure 62: Gender Ratio (M/F), Turkey, 2005-2010 131Figure 63: Life Expectancy at Birth (Years), Turkey, 2005-2010 132
  9. 9. Figure 64: Life Expectancy at Birth Forecast (Years), Turkey, 2011-2020 133Figure 65: Levels of Education, Turkey, Gross Enrolment (%), 2009 134Figure 66: Students Enrolled (m), Turkey, 2005-2010 135Figure 67: Unemployment Rate (%), Turkey, 2006-2011 136Figure 68: Employment, Turkey, Pharmaceutical Sector, Number of Employees (‘000), 1987-2007137Figure 69: Major Diseases, Turkey, DALYs (Per 100,000 Population), 2004 138Figure 70: Public and Private Hospitals, Turkey, 2005-2010 139Figure 71: MRI Units in Hospitals (Per 100,000 Population), Turkey, 2005-2010 140Figure 72: CT Scan Units in Hospitals (Per 100,000 Population), Turkey, 2005-2010 141Figure 73: Beds (Per 1,000 Population), Turkey, 2005-2010 142Figure 74: Physicians (Per 1,000 Population), Turkey, 2005-2010 143Figure 75: Physicians (Per 1,000 Population), Forecast, Turkey, 2011-2020 144Figure 76: CO2 Emissions (Metric Tons), Turkey, 2005-2010 145Figure 77: Deaths Attributable to the Environment (Per 100,000 Population), Turkey, 2004 146Figure 78: PM10 (µg/m3), Turkey, 2005-2010 147Figure 79: Nurses (Per 1,000 Population), Turkey, 2005-2010 148Figure 80: Pharmacists (Per 100,000 Population), Turkey, 2005-2010 149Figure 81: Dentists (Per 100,000 Population), Turkey, 2005-2010 150Figure 82: Healthcare Expenditure (% of GDP), Turkey, 2005-2010 151Figure 83: Healthcare Expenditure (% of GDP), Turkey, Forecast, 2011-2020 152Figure 84: Drug Expenditure Share ($m), Turkey, 2000-2007 153Figure 85: Drug Expenditure, Turkey, Share (%), 2000-2007 154Figure 86: Healthcare Expenditure Per Capita ($), Turkey, 2001-2007 155Figure 87: Healthcare Expenditure, Turkey, Public-Private Share (%) 2005-2010 156Figure 88: Health R&D Expenditure ($m), Turkey, 2005-2010 157Figure 89: Opportunities and Challenges, Healthcare Market, Turkey, 2011 161Contact: sales@reportsandreports.com for more information.

×